3071 A phase II study of carboplatin (Cb), pemetrexed (PEM), and bevacizumab (Bev) followed by Bev and erlotinib (Erl) maintenance for non-squamous non-small cell lung cancer (NS-NSCLC) with wild-type (WT) EGFR. (September 2015)

Record Type:
Journal Article
Title:
3071 A phase II study of carboplatin (Cb), pemetrexed (PEM), and bevacizumab (Bev) followed by Bev and erlotinib (Erl) maintenance for non-squamous non-small cell lung cancer (NS-NSCLC) with wild-type (WT) EGFR. (September 2015)
Main Title:
3071 A phase II study of carboplatin (Cb), pemetrexed (PEM), and bevacizumab (Bev) followed by Bev and erlotinib (Erl) maintenance for non-squamous non-small cell lung cancer (NS-NSCLC) with wild-type (WT) EGFR
Authors:
Takashina, T.
Asahina, H.
Yamada, N.
Harada, M.
Nakano, K.
Yokouchi, H.
Kanazawa, K.
Takamura, K.
Ogi, T.
Harada, T.
Honjo, O.
Morikawa, N.
Kinoshita, I.
Honda, R.
Amano, T.
Akita, H.
Isobe, H.
Nishimura, M.
Abstract:
Is Part Of:
European journal of cancer. Volume 51:(2015)Supplement 3
Journal:
European journal of cancer
Issue:
Volume 51:(2015)Supplement 3
Issue Display:
Volume 51, Issue 3 (2015)
Year:
2015
Volume:
51
Issue:
3
Issue Sort Value:
2015-0051-0003-0000
Page Start:
S620
Page End:
Publication Date:
2015-09
Subjects:
Cancer -- Periodicals
Neoplasms -- Periodicals
Cancer -- Périodiques
Cancer
Tumors
Electronic journals
Periodicals
Electronic journals
616.994
Journal URLs:
http://www.sciencedirect.com/science/journal/09598049 ↗
http://rzblx1.uni-regensburg.de/ezeit/warpto.phtml?colors=7&jour_id=2879 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/09598049 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/09598049 ↗
http://www.elsevier.com/journals ↗
DOI:
10.1016/S0959-8049(16)31712-9 ↗
Languages:
English
ISSNs:
0959-8049
Deposit Type:
Legaldeposit
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:
British Library DSC - 3829.725100
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:
2033.xml